Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AZD-6793 by AstraZeneca for Inflammation: Likelihood of Approval
AZD-6793 is under clinical development by AstraZeneca and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs...
Adavosertib by AstraZeneca for Vaginal Cancer: Likelihood of Approval
Adavosertib is under clinical development by AstraZeneca and currently in Phase I for Vaginal Cancer. According to GlobalData, Phase I...
Adavosertib by AstraZeneca for Cervical Cancer: Likelihood of Approval
Adavosertib is under clinical development by AstraZeneca and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
Ceralasertib by AstraZeneca for Solid Tumor: Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Pancreatic Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
AZD-0780 by AstraZeneca for Cardiovascular Disease: Likelihood of Approval
AZD-0780 is under clinical development by AstraZeneca and currently in Phase II for Cardiovascular Disease. According to GlobalData, Phase II...
Osimertinib mesylate by AstraZeneca for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Osimertinib mesylate is under clinical development by AstraZeneca and currently in Phase II for Non-Small Cell Lung Carcinoma. According to...
Olaparib by AstraZeneca for Osteosarcoma: Likelihood of Approval
Olaparib is under clinical development by AstraZeneca and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs...
Olaparib by AstraZeneca for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Olaparib is under clinical development by AstraZeneca and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...
AZD-5462 by AstraZeneca for Congestive Heart Failure (Heart Failure): Likelihood of Approval
AZD-5462 is under clinical development by AstraZeneca and currently in Phase II for Congestive Heart Failure (Heart Failure). According to...
Tozorakimab by AstraZeneca for Asthma: Likelihood of Approval
Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II drugs...
Durvalumab by AstraZeneca for Soft Tissue Sarcoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase...
Olaparib by AstraZeneca for Pancreatic Cancer: Likelihood of Approval
Olaparib is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
Olaparib by AstraZeneca for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Olaparib is under clinical development by AstraZeneca and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...
Ceralasertib by AstraZeneca for Solid Tumor: Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
AZD-8630 by AstraZeneca for Asthma: Likelihood of Approval
AZD-8630 is under clinical development by AstraZeneca and currently in Phase I for Asthma. According to GlobalData, Phase I drugs...
Risk adjusted net present value: What is the current valuation of AstraZeneca's MEDI-7352?
MEDI-7352 is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Diabetic Neuropathic Pain. According to...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Datopotamab deruxtecan?
Datopotamab deruxtecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Pre-Registration program in Non-Small Cell Lung Cancer....
Risk adjusted net present value: What is the current valuation of AstraZeneca's Volrustomig?
Volrustomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Cervical Cancer. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Gefurulimab?
Gefurulimab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Myasthenia Gravis. According to Globaldata,...